Hospital
Memorial Medical Center of West Michigan
Memorial Medical Center of West Michigan was paid $11.76M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoMEMORIAL MEDICAL CENTER OF WEST MICHIGAN
LUDINGTON, MI 49431
LUDINGTON, MI 49431
33aNPI1972589489assigned 12/16/2005
33bProvider typeRural Acute Care Hospital
28Total paid$11.76M
24GClaims480,702
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Michigan
Rank by total paid#4 of 5
Median peer was paid$13.93M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,563 | $1.21M | |
| 2019 | 49,204 | $1.05M | |
| 2020 | 60,315 | $1.36M | |
| 2021 | 88,474 | $2.13M | |
| 2022 | 81,924 | $2.06M | |
| 2023 | 80,842 | $2.10M | |
| 2024incomplete | 67,380 | $1.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 14,075 | 13,089 | $2.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 15,581 | 14,733 | $1.96M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,025 | 3,773 | $1.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.2% | 8,618 | 7,662 | $845K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 6,471 | 6,271 | $466K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 15,068 | 4,466 | $403K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,768 | 2,696 | $399K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 6,286 | 6,050 | $366K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,221 | 1,570 | $209K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 2,189 | 2,159 | $206K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 3,195 | 2,517 | $186K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 4,606 | 4,385 | $173K |
219 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 7,066 | $146K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 4,647 | $134K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,693 | $110K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,658 | $105K |
| 86900 | <1% | 2,482 | $87K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,470 | $87K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,812 | $87K |
| 80061 | Lipid panel | <1% | 6,882 | $84K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,783 | $83K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,870 | $80K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,388 | $75K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 714 | $73K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,805 | $72K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,665 | $62K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 516 | $58K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 2,223 | $56K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 398 | $56K |
| 80053 | Comprehensive metabolic panel | <1% | 24,799 | $54K |
| 80050 | General health panel | <1% | 1,839 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,989 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,492 | $48K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,981 | $48K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 247 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,123 | $47K |
| 76830 | Ultrasound, transvaginal | <1% | 734 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,380 | $40K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,506 | $38K |
| 97162 | <1% | 804 | $37K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,660 | $32K |
| G0378 | Hospital observation service, per hour | <1% | 167 | $32K |
| 82947 | <1% | 2,801 | $28K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,037 | $26K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,703 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,108 | $25K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 142 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,546 | $17K |
| 82728 | <1% | 2,697 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,957 | $15K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 315 | $14K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 1,218 | $13K |
| 82607 | <1% | 1,939 | $12K | |
| 86780 | <1% | 1,534 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,595 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 133 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,040 | $10K |
| 93975 | <1% | 82 | $10K | |
| 83550 | <1% | 2,641 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 394 | $10K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 249 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,998 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 794 | $9K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 14 | $9K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 461 | $9K |
| 83655 | <1% | 1,236 | $8K | |
| 83540 | <1% | 2,777 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 96 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 628 | $8K |
| 84439 | <1% | 2,099 | $8K | |
| 73630 | <1% | 945 | $7K | |
| 73562 | <1% | 564 | $7K | |
| 84702 | <1% | 1,795 | $7K | |
| 85027 | <1% | 3,486 | $7K | |
| 97161 | <1% | 145 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,030 | $6K |
| 87077 | <1% | 2,423 | $6K | |
| 87081 | <1% | 3,546 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 105 | $6K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 419 | $5K |
| 87653 | <1% | 291 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 25 | $5K |
| 81001 | <1% | 15,522 | $5K | |
| 83735 | <1% | 5,515 | $5K | |
| 73610 | <1% | 723 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 324 | $5K |
| 87186 | <1% | 1,762 | $5K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 453 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 49 | $4K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 36 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 193 | $4K |
| 73030 | <1% | 348 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 231 | $4K |
| 85610 | <1% | 3,930 | $4K | |
| 82570 | <1% | 2,017 | $4K | |
| 82746 | <1% | 630 | $4K | |
| 73110 | <1% | 338 | $4K | |
| 0002A | <1% | 115 | $4K | |
| 72100 | <1% | 120 | $4K | |
| 74018 | <1% | 162 | $4K | |
| 87205 | <1% | 2,409 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 135 | $4K |
| 0012A | <1% | 93 | $3K | |
| 87340 | <1% | 1,391 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| 83880 | <1% | 999 | $3K | |
| 0001A | <1% | 127 | $3K | |
| 82043 | <1% | 1,014 | $3K | |
| 73130 | <1% | 371 | $3K | |
| 70498 | <1% | 14 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 164 | $3K |
| 86140 | <1% | 1,742 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 55 | $2K |
| 0011A | <1% | 92 | $2K | |
| 96376 | <1% | 1,243 | $2K | |
| 94060 | <1% | 14 | $2K | |
| 93971 | <1% | 29 | $2K | |
| 86038 | <1% | 274 | $2K | |
| 87070 | <1% | 628 | $1K | |
| 76770 | <1% | 24 | $1K | |
| 80076 | <1% | 406 | $1K | |
| 84100 | <1% | 1,617 | $1K | |
| 76801 | <1% | 24 | $1K | |
| 85652 | <1% | 1,541 | $1K | |
| 83690 | <1% | 5,105 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 131 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,353 | $1K |
| 74019 | <1% | 212 | $947.27 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 20 | $930.06 |
| 81025 | <1% | 6,185 | $925.35 | |
| 84403 | <1% | 67 | $877.28 | |
| 85730 | <1% | 1,555 | $793.27 | |
| 82565 | <1% | 918 | $603.92 | |
| 87147 | <1% | 362 | $551.82 | |
| 84156 | <1% | 524 | $547.46 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,079 | $529.75 |
| 73564 | <1% | 27 | $524.36 | |
| 83001 | <1% | 50 | $500.81 | |
| 86850 | <1% | 2,329 | $495.88 | |
| 82950 | <1% | 182 | $480.26 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 89 | $432.73 |
| 84466 | <1% | 86 | $405.30 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 82 | $394.85 |
| 82150 | <1% | 910 | $363.13 | |
| 82670 | <1% | 25 | $354.94 | |
| 85007 | <1% | 460 | $332.51 | |
| 82550 | <1% | 194 | $257.08 | |
| 72110 | <1% | 16 | $233.04 | |
| 86787 | <1% | 337 | $201.92 | |
| 73502 | <1% | 12 | $196.58 | |
| 83605 | <1% | 2,092 | $191.90 | |
| 85379 | <1% | 1,089 | $182.84 | |
| 84550 | <1% | 97 | $181.32 | |
| 84484 | <1% | 4,265 | $172.90 | |
| 87807 | <1% | 343 | $167.42 | |
| 85055 | <1% | 13 | $165.34 | |
| 83516 | <1% | 25 | $160.96 | |
| 86431 | <1% | 58 | $155.13 | |
| 83615 | <1% | 154 | $152.17 | |
| 86762 | <1% | 439 | $151.33 | |
| 87088 | <1% | 68 | $143.97 | |
| 82784 | <1% | 27 | $141.92 | |
| 70496 | <1% | 13 | $100.63 | |
| 82805 | <1% | 56 | $87.04 | |
| 86200 | <1% | 12 | $85.57 | |
| 86618 | <1% | 13 | $85.50 | |
| 86376 | <1% | 12 | $74.30 | |
| 82248 | <1% | 139 | $66.30 | |
| 82533 | <1% | 13 | $62.44 | |
| 82077 | <1% | 1,020 | $60.40 | |
| 74022 | <1% | 149 | $57.04 | |
| 87420 | <1% | 79 | $49.35 | |
| 73140 | <1% | 17 | $48.48 | |
| 73080 | <1% | 13 | $47.36 | |
| 87400 | <1% | 84 | $44.47 | |
| 87040 | <1% | 265 | $31.21 | |
| 85651 | <1% | 31 | $27.34 | |
| 82247 | <1% | 27 | $22.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,331 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,898 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,498 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 7,125 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 1,359 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 7,892 | $0.00 |
| A9270 | Non-covered item or service | 0% | 115 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,218 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 119 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 555 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,406 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,544 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 737 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 302 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 458 | $0.00 |
| 3017F | 0% | 13 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 118 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 25 | $0.00 |
| 87808 | 0% | 69 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 31 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 143 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 140 | $0.00 |
| 12001 | 0% | 25 | $0.00 | |
| 91301 | 0% | 176 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 26 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
| 86901 | 0% | 152 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 12 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 33 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 19 | $0.00 |
| 76377 | 0% | 15 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 8,533 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 2,361 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 635 | $0.00 |
| 80179 | 0% | 529 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 6,490 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,233 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 4,503 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 4,516 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 5,812 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,047 | $0.00 |
| 90715 | 0% | 14 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 26 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 228 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,555 | $0.00 |
| 91300 | 0% | 238 | $0.00 | |
| 80143 | 0% | 576 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 41 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 27 | $0.00 |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 14 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOSTAL, DREW (REGIONAL MARKET LEADER)